ROIV — Roivant Sciences Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousLarge CapFalling Star

Annual income statement for Roivant Sciences, fiscal year end - March 31st, USD millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	R2023 March 31st	R2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	23.8	55.3	31.5	32.7	29.1
Cost of Revenue
Gross Profit	21.7	46.3	28.5	31.1	28.1
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	979	1,335	909	-4,497	1,029
Operating Profit	-956	-1,280	-877	4,530	-1,000
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-899	-924	-885	4,568	-682
Provision for Income Taxes
Net Income After Taxes	-900	-924	-889	4,546	-730
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-809	-845	-1,009	4,349	-172
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-809	-845	-1,009	4,349	-172
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.29	-0.783	-0.988	1.44	-0.853
Dividends per Share